Looking back: 2021’s Pharmacology Consults peered beyond COVID-19
Click Here to Manage Email Alerts
To mark the end of 2021, we compiled a list of this year’s Pharmacology Consult columns, in which Healio’s contributing PharmDs peered beyond COVID-19 into therapies and vaccines for a range of infectious diseases.
The topics they covered included therapies for HIV, emerging influenza vaccine technologies and the intersection of stewardship and practice. Below are the 11 columns we published this year.
Long-acting injectable PrEP: An exciting alternative
Jennifer Ross, PharmD, discussed the “exciting results” of studies assessing long-acting injectable PrEP and its potential to loosen the grip of the HIV epidemic. Read more.
Strongyloides hyperinfection and its association with COVID-19 treatment
Infectious Disease News Editorial Board Member Jeff Brock, PharmD, MBA, BCPS-AQ ID, wrote about the potential complication of Strongyloides hyperinfection syndrome in patients taking corticosteroids for COVID-19. Read more.
Where acne and antimicrobial stewardship meet
“Antibiotics have been a mainstay of acne treatment for decades,” but their use can cause antibiotic resistance and the drugs carry the risk for side effects, according to Hannah Van Ochten, PharmD, MPH, and Kati Shihadeh, PharmD, BCIDP. In this column, they discussed the importance of antibiotic stewardship when treating patients with acne. Read more.
Pandemic strains resources for HAI prevention and surveillance
Kelly M. Percival, PharmD, BCPS-AQ ID, addressed the impact of the COVID-19 pandemic on health care systems, including in the prevention of hospital-acquired infections. Read more.
The emergence and reemergence of tocilizumab for COVID-19
Jennifer Ross, PharmD, reviewed data on tocilizumab, a recombinant monoclonal antibody, in the setting of COVID-19. Read more.
Antifungal stewardship: Core elements to success
Infectious Disease News Editorial Board Member Jeff Brock, PharmD, MBA, BCPS-AQ ID, reported on an interdisciplinary expert panel that met to developed core elements that relate specifically to antifungal stewardship. Read more.
What’s in the pipeline for multidrug-resistant HIV infections?
Shannon Ketchum, PharmD, and Kati Shihadeh, PharmD, BCIDP, wrote about therapeutic options for adults with heavily treatment-experienced HIV-1 infection and virologic failure. Read more.
The present and future of flu vaccine production technologies
Kelly M. Percival, PharmD, BCPS-AQ ID, discussed egg- vs. cell-based influenza vaccines, as well as experimental vaccines in the pipeline — specifically those that rely on messenger RNA technology. Read more.
Prophylactic and therapeutic RSV options amid fluctuating seasonality
Curative therapies for respiratory syncytial virus do not exist, driving the need for continued optimization of current preventive and treatment efforts. Jennifer Ross, PharmD, reviewed the prophylactic and treatment options that are available for RSV. Read more.
Mycoplasma genitalium: A formidable foe in need of new treatment, diagnostic options
Infectious Disease News Editorial Board Member Jeff Brock, PharmD, MBA, BCPS-AQ ID, said that emerging resistance and limited treatment options for patients with Mycoplasma genitalium present significant challenges for managing the infection. However, some treatments being studied are showing promise. Read more.
Prevention and treatment of COVID-19 in pediatric patients
Kira Voyer, PharmD, and Kati Shihadeh, PharmD, BCIDP, discussed emerging COVID-19 prevention and treatment options for children amid a continued rise in the number of pediatric cases. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts